Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

HealthRX vs Wellorithm

Two GLP-1 desks, one scoreboard. We put HealthRX and Wellorithm head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 7 · Grade B

HealthRX

Visit HealthRX Full brief →
vs
No. 39 · Grade C

Wellorithm

Visit Wellorithm Full brief →

The verdict

HealthRX takes this head-to-head.

HealthRX scores 86 to 58 on our six-factor Brief Score — A LegitScript-certified, physician-supervised desk (healthrx.com) whose real hook is breadth: injectable and a rare oral GLP tablet, on both molecules, with transparent no-insurance monthly pricing.

That doesn't make Wellorithm a bad call — it's best for readers who specifically want an oral dissolving tablet and will complete an intake before learning any cost. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
85
40
Supply Reliability
85
70
Transparency
83
28
Access Breadth
91
84
Clinical Oversight
89
40
Track Record
81
58
HealthRXBrief Score 86 · 58Wellorithm

Price, coverage & the tracker

HealthRXWellorithm
Brief Score86/100 (B)58/100 (C)
Semaglutide$189/moPricing not published
Tirzepatide$349/moPricing not published
CoverageNot publicly listed49 states (not Louisiana)
Brand-name accessYesYes
Oral / sublingualYesYes
On the trackerStableprice stableStableprice stable

HealthRX: Company-stated tiers held flat this cycle; the LegitScript badge and a rare oral GLP tablet are the draw, but some tiers are self-reported rather than checkout-verified.

Wellorithm: Nothing to track — no price appears anywhere on the public site, and the pricing page 404s.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.